Phase III study of finerenone added to standard of care for chronic kidney disease in patients with type 2 diabetes meets primary endpoint

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist. In the FIDELO-DKD study it reduced the combined risk of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over 4 weeks, or renal death.


Biospace Inc.